fertility care company Carafem launches a new process that aims to provide faster access to abortion pills.
Patients living in Illinois, Colorado, New Mexico and Maryland can be assessed for prescription drugs without the mandatory telephone or video call. After filling out a form on Carafem’s website, medical staff members review the patient’s history and share information about the process of using the pills and options for care.
The company said a medical professional would then approve the prescription, and the pills would be sent in the mail. patients can also use The company’s virtual assistant Kara, who can track shipments, provide more information about the tablets and answer questions.
“Abortion should be available to everyone who wants it, and Carafem’s immediate evaluation for abortion pills is one way to make it a little easier,” Melissa Grant, Carafem’s chief operating officer and cofounder, said in a statement. “Our medical professionals strive to make abortion services more convenient, personalized, and private without compromising on high-quality care.”
interest in medication abortion, a The two-pill regimen, used to terminate pregnancy through 10 weeks’ gestation, grew in the wake of the Supreme Court’s Dobbs decision, which overturned Roe v. Wade. An analysis published in November found that online requests for prescription drug assistance increased after the draft was leaked and after the decision was formally announced.
The drug’s use for abortion has also increased rapidly since the FDA approved mifepristone for its use in 2000. According to the Guttmacher Institute, medication abortions made up more than half of all facility-based abortions in 2020, compared to 39% in 2017.
Earlier this month the FDA said it would Allow retail pharmacies to offer abortion pills for the first time in the U.S. Previously, they were only available through certain mail-order pharmacies, certified doctors, or clinics.
anti abortion groups Pills are increasingly being targeted as more states limit abortions after the RoA. In November, abortion opponents filed a lawsuit in federal court in Texas arguing that the FDA did not have authority to approve mifepristone.
Agency responded to the lawsuit in a filing this week that said “the public interest would be harmed by effectively withdrawing from the market a safe and effective drug that has been legitimately on the market for 22 years.”